Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016947 | 0.87 | KMT2A (0.41) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL6886843 | 0.87 | KMT2A (0.49) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL5961335 | 0.87 | NR1H4 (0.48) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL5961345 | 0.87 | ACKR3 (0.42) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL6016986 | 0.86 | NR1H4 (0.51) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL6016983 | 0.85 | NR1H4 (0.47) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL5961349 | 0.85 | KMT2A (0.46) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL5961323 | 0.84 | NPC1 (0.47) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL6016894 | 0.83 | KMT2A (0.50) | KMT2AMEN1NR1H4PTGDR2NPC1 | |
| SCHEMBL6016950 | 0.82 | NR1H4 (0.59) | KMT2AMEN1NR1H4PTGDR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633726-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | Actimis Pharmaceuticals, Inc., (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004096777-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |